Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVICO longitudinal follow-up of SARS-CoV-2 immunity in immunocompromised populations in Belgium
2022-002531-56Phase 4Active
- Sponsor
- Sciensano
- Start
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Sciensano. Primary endpoint: Binding and neutralizing antibody levels against predominant SARS-CoV-2 variant of concern. Started Nov 2022; status: active.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-002531-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002531-56.